Literature DB >> 14668439

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

Klaus Godl1, Josef Wissing, Alexander Kurtenbach, Peter Habenberger, Stephanie Blencke, Heidrun Gutbrod, Kostadinos Salassidis, Matthias Stein-Gerlach, Andrea Missio, Matt Cotten, Henrik Daub.   

Abstract

Small molecule inhibitors of protein kinases are widely used in signal transduction research and are emerging as a major class of drugs. Although interpretation of biological results obtained with these reagents critically depends on their selectivity, efficient methods for proteome-wide assessment of kinase inhibitor selectivity have not yet been reported. Here, we address this important issue and describe a method for identifying targets of the widely used p38 kinase inhibitor SB 203580. Immobilization of a suitable SB 203580 analogue and thoroughly optimized biochemical conditions for affinity chromatography permitted the dramatic enrichment and identification of several previously unknown protein kinase targets of SB 203580. In vitro kinase assays showed that cyclin G-associated kinase (GAK) and CK1 were almost as potently inhibited as p38alpha whereas RICK [Rip-like interacting caspase-like apoptosis-regulatory protein (CLARP) kinase/Rip2/CARDIAK] was even more sensitive to inhibition by SB 203580. The cellular kinase activity of RICK, a known signal transducer of inflammatory responses, was already inhibited by submicromolar concentrations of SB 203580 in intact cells. Therefore, our results warrant a reevaluation of the vast amount of data obtained with SB 203580 and might have significant implications on the development of p38 inhibitors as antiinflammatory drugs. Based on the procedures described here, efficient affinity purification techniques can be developed for other protein kinase inhibitors, providing crucial information about their cellular modes of action.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668439      PMCID: PMC307585          DOI: 10.1073/pnas.2535024100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Exploiting features of adenovirus replication to support mammalian kinase production.

Authors:  Matt Cotten; Kerstin Stegmueller; Jan Eickhoff; Miriam Hanke; Katrin Herzberger; Thomas Herget; Axel Choidas; Henrik Daub; Klaus Godl
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

Review 2.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

3.  Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Authors:  S P Davies; H Reddy; M Caivano; P Cohen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

4.  Optimization of guanidination procedures for MALDI mass mapping.

Authors:  Richard L Beardsley; James P Reilly
Journal:  Anal Chem       Date:  2002-04-15       Impact factor: 6.986

5.  MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis.

Authors:  A Kotlyarov; A Neininger; C Schubert; R Eckert; C Birchmeier; H D Volk; M Gaestel
Journal:  Nat Cell Biol       Date:  1999-06       Impact factor: 28.824

6.  Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor.

Authors:  Marie Knockaert; Karen Wieking; Sophie Schmitt; Maryse Leost; Karen M Grant; Jeremy C Mottram; Conrad Kunick; Laurent Meijer
Journal:  J Biol Chem       Date:  2002-04-18       Impact factor: 5.157

7.  Involvement of receptor-interacting protein 2 in innate and adaptive immune responses.

Authors:  Arnold I Chin; Paul W Dempsey; Kevin Bruhn; Jeff F Miller; Yang Xu; Genhong Cheng
Journal:  Nature       Date:  2002-03-14       Impact factor: 49.962

8.  RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems.

Authors:  Koichi Kobayashi; Naohiro Inohara; Lorraine D Hernandez; Jorge E Galán; Gabriel Núñez; Charles A Janeway; Ruslan Medzhitov; Richard A Flavell
Journal:  Nature       Date:  2002-03-14       Impact factor: 49.962

Review 9.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.

Authors:  Renaud Capdeville; Elisabeth Buchdunger; Juerg Zimmermann; Alex Matter
Journal:  Nat Rev Drug Discov       Date:  2002-07       Impact factor: 84.694

10.  Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein.

Authors:  Henrik Daub; Stephanie Blencke; Peter Habenberger; Alexander Kurtenbach; Julia Dennenmoser; Josef Wissing; Axel Ullrich; Matt Cotten
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more
  91 in total

1.  Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines.

Authors:  Romel Somwar; Hediye Erdjument-Bromage; Erik Larsson; David Shum; William W Lockwood; Guangli Yang; Chris Sander; Ouathek Ouerfelli; Paul J Tempst; Hakim Djaballah; Harold E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 2.  The role of targeted chemical proteomics in pharmacology.

Authors:  Chris W Sutton
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  A dual role for receptor-interacting protein kinase 2 (RIP2) kinase activity in nucleotide-binding oligomerization domain 2 (NOD2)-dependent autophagy.

Authors:  Craig R Homer; Amrita Kabi; Noemí Marina-García; Arun Sreekumar; Alexey I Nesvizhskii; Kourtney P Nickerson; Arul M Chinnaiyan; Gabriel Nuñez; Christine McDonald
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

4.  Simplified proteomics approach to discover protein-ligand interactions.

Authors:  Youngil Chang; Jonathan P Schlebach; Ross A VerHeul; Chiwook Park
Journal:  Protein Sci       Date:  2012-07-23       Impact factor: 6.725

5.  Protein kinase affinity reagents based on a 5-aminoindazole scaffold.

Authors:  Ratika Krishnamurty; Amanda M Brock; Dustin J Maly
Journal:  Bioorg Med Chem Lett       Date:  2010-10-21       Impact factor: 2.823

6.  Peptide-siRNA nanocomplexes targeting NF-κB subunit p65 suppress nascent experimental arthritis.

Authors:  Hui-fang Zhou; Huimin Yan; Hua Pan; Kirk K Hou; Antonina Akk; Luke E Springer; Ying Hu; J Stacy Allen; Samuel A Wickline; Christine T N Pham
Journal:  J Clin Invest       Date:  2014-08-26       Impact factor: 14.808

7.  Sex-specific control of central nervous system autoimmunity by p38 mitogen-activated protein kinase signaling in myeloid cells.

Authors:  Dimitry N Krementsov; Rajkumar Noubade; Julie A Dragon; Kinya Otsu; Mercedes Rincon; Cory Teuscher
Journal:  Ann Neurol       Date:  2014-01       Impact factor: 10.422

8.  Exploring the specificity of the PI3K family inhibitor LY294002.

Authors:  Severine I Gharbi; Marketa J Zvelebil; Stephen J Shuttleworth; Tim Hancox; Nahid Saghir; John F Timms; Michael D Waterfield
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

9.  A directed approach for engineering conditional protein stability using biologically silent small molecules.

Authors:  Lystranne A Maynard-Smith; Ling-Chun Chen; Laura A Banaszynski; A G Lisa Ooi; Thomas J Wandless
Journal:  J Biol Chem       Date:  2007-07-01       Impact factor: 5.157

10.  p38 regulates pigmentation via proteasomal degradation of tyrosinase.

Authors:  Barbara Bellei; Vittoria Maresca; Enrica Flori; Angela Pitisci; Lionel Larue; Mauro Picardo
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.